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Background: Shared decision-making and patients’ choice of interventions are areas of increasing importance, not
least seen in the light of the fact that chronic conditions are increasing, interventions considered important for
public health, and still non-acceptance of especially risk-reducing treatments of cardiovascular diseases (CVD) is
prevalent. A better understanding of patients’ medication-taking behavior is needed and may be reached by
studying the reasons why people accept or decline medication recommendations. The aim of this paper was to
identify factors that may influence people’s decisions and reasoning for accepting or declining a cardiovascular
preventive medication offer.
Methods: From a random sample of 4,000 people aged 40–59 years in a Danish population, 1,169 participants
were asked to imagine being at increased risk of cardiovascular disease and being offered a preventive medication.
After receiving ‘complete’ information about effectiveness of the medication they were asked whether they would
accept medication. Finally, they were asked about reasons for the decision.
Results: A total of 725 (67%) of 1,082 participants accepted the medication offer. Even quite large effects of
medication (up to 8 percentage points absolute risk reduction) had a smaller impact on acceptance to medication
than personal experience with cardiovascular disease. Furthermore, increasing age of the participant and living with
a partner were significantly associated with acceptance. Some 45% of the respondents accepting justified their
choice as being for health reasons, and they were more likely to be women, live alone, have higher income and
higher education levels. Among those who did not accept the medication offer, 56% indicated that they would
rather prefer to change lifestyle.
Conclusions: Medication effectiveness seems to have a moderate influence on people’s decisions to accept
preventive medication, while factors such as personal experience with cardiovascular disease may have an equally
strong or stronger influence, indicating that practitioners could do well to carefully identify the reasons for their
patients’ treatment decisions.
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Shared decision-making is based on the principle of pa-
tient autonomy [1,2] and practitioners of shared
decision-making aim to assist patients in making deci-
sions that are in line with their own values and judg-
ments. If so, there is no universally “correct” decision,
and the role of the practitioner is to inform and help the
patient think about his or her values and opinions. It
then becomes evident that studies evaluating why
patients do or do not accept treatment proposals are
necessary.
It is also well-known to healthcare personnel that
patients do not always take medication as prescribed [3].
Adherence may be improved if patients’ decisions on
whether to initiate medication are in accordance with
their personal expectations and attitudes [4]. Expecta-
tions may be based upon knowledge, including the
expected risk reduction resulting from the medication
on offer [5]. Decisions concerning medication accept-
ance may also be influenced by attitudes based on per-
sonal life experiences, including educational attainment
and earlier experiences with the disease in question, ei-
ther personally or in the family. Earlier studies provide
understanding of links between patients’ and doctors’
perceptions of the patient’s condition, including know-
ledge of the patient’s reasons for decisions made and
subsequent adherence to medication [6,7]. Acknowledg-
ing the link between informed consent for medication
and subsequent adherence, practitioners may therefore
do well to try to gain more knowledge and understand-
ing of their patients’ attitudes and fundamental health
beliefs in order to improve communication, correct mis-
interpretations, and aid the patient in making optimal
health decisions.
Lifestyle changes and medication are widely recom-
mended in the prevention of cardiovascular disease
(CVD). Recent studies from the US argue that aggressive
and targeted interventions are needed to enhance pro-
vider and patient adherence to guidelines for CVD risk
reduction [8,9]. Other studies define non-acceptance and
non-adherence to prescribed medical treatment as
unrecognized cardiovascular risk factors, resulting in a
significant burden on health care resources [10,11]. In a
Canadian study, the authors suggest policies such as
education programmes for both the public and for
healthcare professionals to avoid underuse of statins
[12].
Although several preventive interventions for chronic
diseases such as CVD exist, this population-based study
focuses on cardiovascular preventive medication and
evaluates communication of effectiveness of a cardiovas-
cular preventive medication in the context of other per-
sonal characteristics that may also influence treatment
acceptance. The target group was aged 40 to 59 years,and thus at some potential risk of cardiovascular disease
due to age (with or without other risk factors), and able
to relate to the hypothetical scenario in question. The
aim of this study was to identify factors that may influ-
ence people’s decisions and subsequent reasoning for
accepting or declining cardiovascular preventive
medication.
Methods
During October through November 2005, a random
sample of 4,000 persons aged 40–59 (at 1 January 2005)
in the municipality of Odense (approx. 185,000 inhabi-
tants), Denmark, was invited for an interview. Invitees
were drawn from the Central Office of Civil Registration
(the CPR-Office) under the Ministry for Economic and
Interior Affairs.
No information from medical records was obtained,
but due to age the individuals belonged to a target group
of potential candidates for cardiovascular prevention
therapy. Non-responders were followed up with remin-
ders by letter and/or telephone.
The interviews took place in a university building next
to the university hospital just outside the city centre.
Participants were informed that the interview would be
about preventive health care. For their effort the respon-
dents would receive a gift of either two bottles of wine
or one box of chocolates. Interviews were conducted in
4-hour sessions in the afternoons over a period of six
weeks. Each interview lasted for about 30 minutes.
The design of the interview guide was based on inten-
sive discussions within the research group, two groups
with lay persons and one group with health personnel,
and ultimately on discussions with researchers from the
Danish National Centre for Social Research. A group of
trained interviewers were assigned to conduct the inter-
views. The interview guides were structured with pre-
specified options.
All participants were asked questions on sociodemo-
graphic characteristics, comprising age, gender, marital
status, family income, educational attainment and occu-
pation. They were then asked to imagine being at
increased risk of cardiovascular disease (the baseline
risk) and being offered medication. No medication name
was mentioned, but the features of the medication (ef-
fectiveness and side effects) resembled statins.
Participants were allocated to four different levels of
effectiveness, which regardless of information type was
equivalent to an absolute risk reduction (ARR) of 2%,
4%, 5%, and 10%, and formed the bases for information
about medication effectiveness. Even though they were
initially presented with different formats of information
(relative risk reduction, absolute risk reduction, number
needed to treat, expected prolongation of life, as well as
a pictorial presentation) [13] they were later all
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mation with a combination of all four formats for medi-
cation effectiveness presented, including a pictorial
presentation (see Figure 1 presenting example of pictor-
ial presentation). This “complete” information formed
the basis of the decisions - to accept or not accept treat-
ment - studied in this paper.
This paper reports on data from a study aimed at ex-
ploring the different ways of explaining risk reductions
to lay people [13,14]. The study was powered to test hy-
potheses other than those tested here.
All the different effectiveness formats can be presented
based on the same data, and none of the measures are
more or less correct than the other, but all may affect
decision; In order to minimize bias because of a specific
format we presented “the full package”, and focused on
the participants’ subsequent acceptance or rejection of
cardiovascular preventive medication and the reasons
for their decision. We refer to [13,14] for detailed de-
scription of the underlying design, including details of
the risk information formats, interview guide and infor-
mation cards.
While the initially presented risk format led to differ-
ent acceptance rates [13], these differences were largely
removed when participants had been presented with the
final, “complete” information. We have therefore not
allowed for an effect of the baseline risk and initial risk
format, since all outcomes studied here are obtained
after the final information had been provided.
We constructed the response options based on the
Health Belief Model [15]. For participants who accepted
medication, the options were: “For health reasons”,
“Trust in my GP” or “Responsibility towards my family”.
For participants who declined medication, the options
were: “Too small effect of the medication”, “Wish to
avoid side-effects”, “Do not want the extra expense”,
“Dislike taking medication”, “Find the information diffi-
cult to understand”, “Prefer to change lifestyle”, andFigure 1 Example of pictorial presentation comprised in the
‘complete’ information.“General disbelief in effectiveness of medication”. For
each of the above, participants were asked to pick the
most important reason for the choice made. Finally, all
participants were asked about their personal and family
history of hypercholesterolemia, CVD or stroke, and
asked four questions to capture their numeracy skills.
According to the Act on a Biomedical Research Ethics
Committee System the project was not a biomedical re-
search project and therefore did not need the ethic com-
mittee’s approval. The study was approved by the Danish
Data Protection Agency.
Statistics
The basic response variable was “acceptance of medica-
tion” on a binary scale (yes/no). To identify possible
associations between participants’ characteristics and
medication-taking behavior we first performed simple
and multiple logistic regression modeling in Stata with
acceptance of medication as the dependent variable. As
explanatory variables we used medication effectiveness
(ARR in percent), age, gender, duration of education,
household income, numeracy skills, living with a partner,
personal experience with cardiovascular disease or risk
factors as presence of one or more of the following con-
ditions: previous stroke or heart attack, hypercholester-
olemia, or hypertension, and whether the participant
had experienced cardiovascular disease in the family or
not. The variables medication effectiveness, age and
household income were used as continuous covariates, i.
e. the corresponding odds ratio represents the estimated
relative increase in odds due to a one unit increase in
the covariate (percentage point, year, 100,000 DKK, re-
spectively. US$1.00 = DKK5.90). The other variables
were binary covariates.
In addition, we performed subgroup logistic regression
analyses with people’s reasons for accepting medication
as response variables. The analyses included separate lo-
gistic regression analyses for each of the three different
response variables “For health reasons”, “Trust in my
GP”, and “Responsibility towards the family”. Secondly,
we performed separate subgroup logistic analyses of rea-
sons for declining medication with each of the response
variables “Too small effect of the medication”, “Wish to
avoid side-effects”, “Dislike taking medicine”, and “Ra-
ther change lifestyle”. The options “Do not want the
extra expense”, “Find the information difficult to under-
stand” and “General disbelief in effectiveness of medica-
tion” were excluded from the analysis due to low
frequency (1, 2, and 1 observations, respectively). As ex-
planatory variables for the subgroup analyses we used
medication effectiveness (ARR in percent), age, gender,
duration of education, household income, numeracy
skills, living with a partner, personal experience with car-
diovascular disease or risk factors as presence of one or
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hypercholesterolemia or hypertension, and whether the
participant had experience with cardiovascular disease in
the family or not. The variables were chosen a priori
from considerations based on expectations and know-
ledge within the field. For all estimates we report odds
ratios (OR), and (95% confidence intervals). We chose
logistic regression modeling because the outcome vari-
able “acceptance of medication” is binary. We chose in-
dependent variables that would be plausible predictors
of the outcome. We used non-parametric smoothing to
assess linearity of the response variable on the log-odds
scale with respect to continuous covariates. To build the
model we had a priori established a list of covariates to
include, but used the size of their estimated standard
errors relative to the estimated effect size to judge both
their impact and statistical significance. This was the
case for both continuous and categorical covariates.
Results
Among the 4,000 invited, 1,169 persons participated
(29.2%) and were given the ‘complete’ effectiveness infor-
mation used for the present study. Because we aimed at
exploring motives for accepting or declining the offered
medication, the analyses did not include non-responders
to the question as to whether or not they would accept
the medication offer (n = 85). We assumed that these
individuals could not make the decision whether to
accept or not and thus were unable to state decision
motives. Two individuals had not stated why they hadLay persons invited for intervie
(n=4,000)
Net study sample for current st
(n=1,082)
W
(n
Interviewed
(n=1,491)
E
•D
• D
D
Gross sample for current stud
(n=1,169)
Did nAccepted therapy (n=725) 
Figure 2 Participation flowchart.accepted or declined the medication offer, and were like-
wise excluded from further analyses. Hence 1,082 parti-
cipants were included for analyses (Figure 2).
Baseline characteristics of the 1,082 participants and
participants grouped into those accepting to medication,
respectively those declining, are reported in Table 1.
In total 725 (67%) respondents indicated that they
would accept the medication offer. Table 2 shows crude
and adjusted OR for variables potentially associated with
acceptance of the medication offer.
Effect size of medication and personal experience with
cardiovascular disease were both associated with accept-
ance of the medication offer, the effect of personal experi-
ence with disease equating an 8 percentage point increase
in effect size (measured as ARR) offered in the multivari-
ate model. Significant associations were also found be-
tween acceptance of the medication offer and increasing
age of the participant as well as living with a partner.
Among those accepting medication, the main reasons
were stated as “For health reasons” (46%), “Responsibil-
ity towards the family” (31%), “Trust in my GP” (18%)
and “Other reasons” (4%). Answering “For health rea-
sons” was associated with female gender, longer educa-
tion, and living alone; answering “Trust in my GP” was
associated with increasing age, living with a partner, and
lower income; and answering “Responsibility towards
the family” was associated with male gender and short
education (Table 3).
Among the 357 persons who declined the medication
offer, the main reasons stated were “Prefer to changews 
udy
ere not given complete information 
=322)
xcluded (n=87)
id not know whether to accept therapy or not (n=85)
id not state why they accepted or rejected therapy (n=2)
eclined to participate (n= 2,509)
y
ot accept therapy (n=357)
Table 1 Baseline characteristics of the participants according to acceptance or rejection of medication, and overall
Total Acceptance of medication Rejection of medication
(n = 1,082) (n = 725) (n = 357)
Covariate
Age (yr), median (10–90 percentile) 51 (43;59) 52 (43;59) 50 (42;58)
Female gender 606 (56) 399 (55) 207 (58)
Short education (<10 years)* 395 (37) 273 (38) 122 (35)
Married or living w/ partner 839 (78) 577 (80) 262 (73)
Personal experience w/ cardiovascular disease 404 (37) 309 (43) 95 (27)
Family w/ known cardiovascular disease 441 (42) 305 (43) 136 (39)
Numeracy skills (less than 2 correct answers) 214 (20) 151 (21) 63 (18)
Household income 500-599 500-599 500-599
(1,000 DKK), median (10–90 percentile) (200–299;800–899) (200–299;800–899) (200–299;800–899)
*Short education is defined as education level below lower secondary school including no specialist training or higher academic education.
Values are numbers (%) unless stated otherwise.
Harmsen et al. BMC Medical Informatics and Decision Making 2012, 12:89 Page 5 of 8
http://www.biomedcentral.com/1472-6947/12/89lifestyle” (58%), “Wish to avoid the side-effects” (19%),
“Too small effect” (13%), “Dislike taking medicine” (5%),
“Find the information difficult to understand” (1%), “Do
not want the extra expense” (<1%), “General disbelief in
effectiveness of medication” (0.3%), and “Other reasons”
(4%).
Declining medication and justifying it with “Preference
to change lifestyle” was associated with higher medica-
tion effectiveness, whereas the justification “Too small
effect” was associated with lower medication effective-
ness; answering “Wish to avoid the side-effects” was
associated with short education. No significant associa-
tions were found with the reason “Dislike taking medi-
cine” (Table 4).
We tested for colinearity, and the highest correlation
was observed between “Household income” and “Age”
(r = −0.11). Furthermore, we tested for interactions but
found none.Table 2 Logistic regression analysis of acceptance of medicat
medication)
Independent variables N
Age (per year) 1,08
Female gender (ref. male) 606
Short education (<10 years) (ref. >10 years)* 395
Married or living w/ partner (ref. living alone) 839
Personal experience w/ cardiovascular disease (ref. no experience) 404
Family w/ known cardiovascular disease (ref. no family disease) 441
Numeracy skills (< 2 correct answers) (ref. >2 correct answers) 214
Household income (per 100,000 DKK) 1,01
Extent of medication effectiveness (per% point) 1,08
*Short education is defined as education level below lower secondary school includ
** Adjusted OR accounting simultaneously for all 9 independent variables.
*** In total 101 missing observations due to a missing value for one or more indepFor all regression analyses, coefficient estimates were
relatively insensitive to adjustment for other covariates.
Discussion
Summary of main findings
A total of 67% of participants indicated that they would
decline the medication offer after receiving information
on medication effectiveness. Effectiveness of the inter-
vention and personal experience with cardiovascular dis-
ease were both associated with acceptance of the
medication offer – the effect of personal experience with
disease equated an 8 percentage point increase in effect
size (measured as ARR) offered in the multivariate
model.
Strengths and limitations of the study
Despite incentives to improve participant rates, the over-
all participation rate was low. The response rates forion offer (0 = accepting medication, 1 = declining
Crude OR (95% CI) Adjusted** OR (95% CI) (n = 981***)
2 1.04 (1.02;1.07) 1.03 (1.00;1.05)
0.89 (0.69;1.15) 0.87 (0.66;1.16)
1.17 (0.90;1.53) 1.09 (0.81;1.48)
1.42 (1.05;1.91) 1.56 (1.05;2.32)
2.05 (1.56;2.71) 1.89 (1.40;2.55)
1.19 (0.92;1.55) 1.05 (0.80;1.39)
1.23 (0.89;1.70) 0.98 (0.68;1.42)
4 0.98 (0.92;1.03) 0.94 (0.87;1.01)
2 1.08 (1.03;1.13) 1.08 (1.03;1.14)
ing no specialist training or higher academic education.
endent variables.
Table 3 Logistic regression analysis for each of the main reasons for accepting medication
Factors Adjusted** OR (95% CI)
“For health reasons” “Trust in the GP” “Responsibility towards
the family”
(n = 332/656***) (n = 134/656***) (n = 228/656***)
Age (per year) 0.99 (0.96;1.02) 1.05 (1.01;1.09) 0.98 (0.95;1.01)
Female gender (ref. male) 1.55 (1.12;2.15) 0.86 (0.57;1.31) 0.63 (0.45;0.89)
Short education (<10 years)* (ref. >10 years) 0.41 (0.29;0.59) 1.23 (0.83;1.95) 2.17 (1.50;3.13)
Married or living w/ partner (ref. living alone) 0.57 (0.35;0.91) 2.00 (1.10;3.63) 1.12 (0.67;1.89)
Personal experience w/ cardiovascular disease (ref. no experience) 0.95 (0.68;1.32) 1.41 (0.93;2.14) 0.85 (0.60;1.22)
Family w/ known cardiovascular disease (ref. no family disease) 1.00 (0.72;1.39) 0.78 (0.52;1.19) 1.03 (0.73;1.45)
Numeracy skills (< 2 correct answers) (ref. >2 correct answers) 0.93 (0.61;1.42) 1.06 (0.64;1.76) 1.14 (0.74;1.78)
Household income (per 100,000 DKK) 1.05 (0.96;1.15) 0.80 (0.71;0.90) 1.84 (0.98;1.19)
Extent of medication effectiveness (per% point) 0.97 (0.92;1.03) 0.99 (0.92;1.06) 1.04 (0.98;1.10)
*Short education is defined as education level below lower secondary school including no specialist training or higher academic education.
** Adjusted OR accounting simultaneously for all 9 independent variables.
*** In total 69 missing observations due to a missing value for one or more independent variables.
Harmsen et al. BMC Medical Informatics and Decision Making 2012, 12:89 Page 6 of 8
http://www.biomedcentral.com/1472-6947/12/89individual items among participants were, however, gen-
erally very high, which justifies the complete case ap-
proach of the data analysis.
Compared to the background population, a higher
proportion of participants were women, the participants
had an average annual household income below the na-
tional average of this age group, but had longer educa-
tion than the background population of this age group
[13]. Thus caution is required in generalizing to a wider
section of the Danish population, or to other countries.
The findings of the present study were based on a
large survey among lay people in a hypothetical scenario.
While trying to resemble real life, and a decision to
which people in this age range could relate, the findings
will be but an estimate of reality and real life decision-
making. On the other hand, this setting allowed us toTable 4 Logistic regression analysis for each of the main reas
Factors
“Too sm
(n = 46
Age (per year) 1.00 (0.
Female gender (ref. male) 1.19 (0.
Short education (<10 years)* (ref. >10 years) 1.03 (0.
Married or living w/ partner (ref. living alone) 0.77 (0.
Personal experience w/ cardiovascular disease (ref. no experience) 0.72 (0.
Family w/ known cardiovascular disease (ref. no family disease) 0.98 (0.
Numeracy skills (< 2 correct answers) (ref. > 2 correct answers) 1.60 (0.
Household income (per 100,000 DKK) 0.99 (0.
Extent of medication effectiveness (per% point) 0.78 (0.
*Short education is defined as education level below lower secondary school includ
** Adjusted OR accounting simultaneously for all 9 independent variables.
*** In total 33 missing observations due to a missing value for one or more indepeprovide participants with more detailed, nuanced and
‘complete’ information than in most clinical settings, but
caution is also required in generalizing from hypothet-
ical to real clinical decisions [16].
Comparison with existing literature
The results of this study indicate that the medication ef-
fect seems to have a moderate influence on people’s
decisions to accept preventive medication offers, while
other factors such as a personal experience with cardio-
vascular disease may have an equally strong or stronger
influence on people’s decisions.
In agreement with other studies [17] this study implies
that people with personal experience of cardiovascular
disease have an increased tendency to accept cardiovas-
cular preventive medication. Experience does, however,ons for declining medication
Adjusted** OR (95% CI)
all effect” “Want to avoid
side-effects”
“Dislike taking
medication”
“Rather change
lifestyle”
/324***) (n = 67/324***) (n = 17/324***) (n = 207/324***)
94;1.06) 0.98 (0.93;1.03) 1.05 (0.95;1.16) 1.00 (0.96;1.04)
58;2.42) 0.60 (0.33;1.07) 1.46 (0.45;4.68) 1.40 (0.88;2.23)
58;2.42) 1.89 1.03;3.47) 1.86 (0.60;5.76) 0.64 (0.39;1.06)
30;2.01) 1.49 (0.64;3.47) 1.31 (0.34;5.05) 0.77 (0.40;1.48)
31;1.70) 0.98 (0.50;1.94) 0.83 (0.23;2.99) 1.18 (0.69;2.02)
48;2.00) 0.86 (0.47;1.57) 0.53 (0.16;1.80) 1.34 (0.83;2.15)
66;3.90) 0.80 (0.35;1.82) 2.78 (0.86;8.96) 0.85 (0.45;1.58)
83;1.20) 0.95 (0.81;1.10) 0.75 (0.55;1.03) 1.05 (0.93;1.18)
66;0.93) 0.94 (0.84;1.06) 0.97 (0.80;1.19) 1.10 (1.01;1.20)
ing no specialist training or higher academic education.
ndent variables.
Harmsen et al. BMC Medical Informatics and Decision Making 2012, 12:89 Page 7 of 8
http://www.biomedcentral.com/1472-6947/12/89not appear to influence the reasons for either accepting
or declining the medication offer. It is worth noting that
it was specifically personal experience with cardiovascu-
lar disease themselves, and not among family members,
which appeared to be significantly associated with
acceptance.
Implications for clinical practice and future research
The findings of the study suggest that in real life doctor-
patient consultations, information on treatment effect-
iveness may have an impact on medication acceptance,
but that previous personal experience with illness, at
least with cardiovascular disease, should not be ignored
when trying to capture real patients’ medication-taking
attitudes, values and intentions and to achieve shared
decision-making. Also, cultural and language factors
may play a role, but unfortunately we have no data, here.
These findings may have implications for practitioners
in routine preventive consultations with their patients.
To many practitioners the predominant reason for
recommending medical treatment is the effectiveness of
the drug. However, lay people may not be experienced in
evaluating effectiveness information and they may make
decisions based on heuristics. Often this may be based
on a ‘single most important reason’ [18]. If patients’ pri-
mary concerns are indeed not the effectiveness of a pos-
sible medical treatment, understanding their underlying
reasons for decision-making is important, and a refocus
on the communication between patient and doctor may
be warranted. Practitioners ought not to focus solely on
communicating effectiveness to their patients, but also
on patient characteristics, including discussing values,
expectations, and previous experiences with the individ-
ual patient [19]. Early identification of these beliefs
about medication may be important elements in coun-
seling and informing patients, as well as being aware of
the subtle contextual factors that may trigger intuitive
and emotional decision processes that affect acceptance
of a given medication.
There was some evidence in this study of poor numer-
acy affecting reasons for declining medication (‘dislike
taking medicine’). The fact that effectiveness information
plays only a minor role in patients’ decision-making may
be due to lack of understanding of the given effective-
ness information. If this is also the case among real
patients making decisions about actual treatments, then
further effort should be made to help patients and per-
haps doctors as well in understanding basic statistics
[20]. As noted above regarding cautions in generalisabil-
ity, further research is warranted to explore medication-
taking intentions and associated patient characteristics
in real life, with real patients confronted with actual risk
and effectiveness information and having to make shared
decisions with their doctors or nurses.Conclusions
The level of intervention effectiveness seems to have a
moderate influence on people’s decisions about prevent-
ive medication while other factors may have an equally
strong or stronger influence. The findings suggest that
doctors may do well to discuss the reasons for treatment
decisions with their patients in order to share decision-
making, optimize decisions and perhaps improve
adherence.
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